Condition: Autosomal Dominant Polycystic Kidney Disease · Sponsor: Cantonal Hospital Graubuenden
This study aims to better understand electrolyte handling in patients with autosomal dominant polycystic kidney disease treated with the SGLT2 inhibitor Empagliflozin. Patients will be randomized into two groups and take Empagliflozin or a Placebo for 2 weeks with a wash-out period of 2 weeks. The primary outcome is tubular handling of the divalent ions calcium, phosphate and magnesium. Secondary outcomes include diuresis, safety and tolerability.
This description comes directly from the study's public registry record.
Patrick Hofmann, MD · +4181 256 6305 · hofmannpatrick@bluewin.ch
Thomas Fehr, MD · +4181 256 6305 · medizin@ksgr.ch
Always discuss trial participation with your own doctor first.
| University Hospital Zurich, Division of Nephrology | Zurich, Canton of Zurich, Switzerland | Recruiting |
| Cantonal Hospital Graubuenden | Chur, Kanton Graubünden, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06435858